Navigation Links
3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
Date:2/25/2009

SHENYANG, China, Feb. 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2008 after the US market closes on Wednesday, March 11, 2009.

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on Thursday, March 12, 2009 to discuss its 2008 fourth quarter and full year financial results and recent business activity.

    The conference call may be accessed using the dial-in numbers below:

    International Toll Dial-In Number:     +65 673 57955
    China (Landline):                      800 819 0121
    China (Mobile):                        400 620 8038
    U.K.:                                  080 823 46646
    U.S.:                                  186 651 94004
    H.K.:                                  800 933 053

    Conference ID:                         87494181

A telephone replay will be available shortly after the call until March 19, 2009, at:

    International Dial-In Number:          +61 2 8235 5000
    U.S Dial-in Number:                    186 6 2145 335

    Conference ID:                         87494181

A live webcast of the conference call and the replay will be available on the investor relations page of 3SBio's website at http://www.3sbio.com/en/News/ShowInfo_nnn11.aspx?ID=71 .

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.

For more information, please visit 3SBio on the web at http://www.3sbio.com .

    For more information, please contact:

    Investor Contact:
     Bo Tan, CFO
     3SBio Inc.
     Tel:   +86-24-2581-1820

    Investor Relations (China):
     Peter Schmidt
     FD Beijing
     Tel:   +86-10-8591-1953

    Investor Relations (US):
     Evan Smith, or
     John Capodanno
     FD US
     Tel:   +1-212-850-5600

'/>"/>
SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... (PRWEB) , ... January 12, ... ... disposable devices with short response times capable of performing routine electrochemical biosensing ... disposable screen-printed electrodes provide fast, sensitive detection and quantification of various analytes ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase ... show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ ... treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from ...
(Date:1/11/2017)... -- Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic ... will be attending the 47th Annual World Economic Forum ... 17-20, 2017. This will be Dr. Mehling,s fifth year ... this year,s forum is Responsive and Responsible Leadership; over ... for fostering greater social inclusion and human development. One-third ...
Breaking Biology Technology:
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
Breaking Biology News(10 mins):